iShares JPMorgan USD Emerging Markets Bond ETF vs Erasca Inc. Common Stock — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.12 (market cap $12.87B), while Erasca Inc. Common Stock trades at $15.97 (market cap $5.40B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is far larger — about 2.4× Erasca Inc. Common Stock's market cap, and Erasca Inc. Common Stock is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Erasca Inc. Common Stock for 0 Days on average.
| EMB | ERAS | |
|---|---|---|
Market Cap | $12.87B | $5.40B |
Volume | 14,946,002 | 9,533,185 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $22.47 |
52-Week Low | $90.14 | $2.20 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $5.18B |
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.13 with a slight 0.39% daily gain, though technical indicators signal bearish momentum with moving averages and ADX showing sell signals. The stock faces resistance near $91-92 levels while finding support around $90. Recent dividend announcements for H2-2026 provide income appeal, but fundamental metrics remain undisclosed in current data.
The outlook appears cautious given bearish technical signals and limited fundamental visibility. Investment opportunity rests on income generation through scheduled dividends, while risks include technical weakness and potential market volatility from rising bond yields affecting fixed-income alternatives.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →